What Is a Urothelial Lesion and Should I Be Worried?

A urothelial lesion is any abnormal growth or change in the urothelium, the specialized lining that covers the inside of your bladder, ureters, and parts of your kidneys and urethra. Whether you should worry depends entirely on what kind of lesion it is, because “urothelial lesion” is not a single diagnosis. It spans a wide spectrum, from completely harmless tissue reactions to aggressive cancers. Most people encounter the term after a cystoscopy report or a pathology result, and the uncertainty can be unsettling. The reality is that many urothelial lesions are benign or very low risk, but some demand prompt treatment and long-term monitoring.

What the Urothelium Actually Does

The urothelium is a layered wall of specialized cells that lines your urinary tract from the kidneys down to the urethra. It is built to handle an unforgiving environment: it stretches as the bladder fills, withstands osmotic pressure, and acts as a barrier so toxic waste products in urine do not seep into the body’s deeper tissues. The urothelium is made up of three cell types (basal, intermediate, and umbrella cells), each playing a distinct role in keeping that barrier intact.¹ When something disrupts this lining, whether it is chronic irritation, infection, chemical exposure, or a genetic mutation, the result can be a lesion. The word “lesion” in pathology just means an area of tissue that looks abnormal under a microscope or during an exam. It says nothing, on its own, about whether that abnormality is dangerous.

The Spectrum From Benign to Malignant

Urothelial lesions are broadly divided into two camps: those that are benign or precancerous, and those that are cancerous. Within each camp, there are further subcategories that carry very different outlooks. The World Health Organization classification system groups these lesions along a continuum that includes simple tissue changes (like metaplasia), precancerous flat lesions (like dysplasia and carcinoma in situ), and frank tumors of varying grades.² Where your lesion falls on this spectrum is what determines whether you should be concerned, and how concerned you should be.

Benign Lesions That Look Alarming

Some of the most common urothelial lesions turn out to be completely benign tissue reactions that can mimic cancer on a cystoscopy screen. Chronic irritation from infections, catheter use, or bladder stones can cause the urothelium to form small inward folds called von Brunn’s nests. These nests can develop further into conditions called cystitis cystica or cystitis glandularis, where the lining cells change shape but remain noncancerous. The typical form of cystitis glandularis is generally considered benign, though a rarer intestinal subtype, which produces mucus-secreting cells resembling colon tissue, gets more attention from pathologists.³ These conditions can form visible masses that look worrying during cystoscopy, sometimes prompting biopsies or even surgical removal before the tissue is confirmed to be benign.⁴

The list of benign conditions that can be mistaken for urothelial cancer is surprisingly long. It includes nephrogenic adenoma, polypoid cystitis, fibroepithelial polyps, inflammatory reactions to prior BCG treatment, and several others. Each has distinct features under a microscope, but some have concerning histological characteristics that make accurate diagnosis a real challenge, even for experienced pathologists.⁵ If your biopsy report mentions any of these, the main takeaway is usually reassurance: the tissue is not cancerous, though your doctor may want to keep an eye on it.

Benign Tumors With an Excellent Outlook

Not every urothelial tumor is cancer. Inverted urothelial papilloma is a rare, noninvasive growth that accounts for roughly 1–2% of urothelial tumors. It typically appears as a small, smooth, stalk-like mass during cystoscopy and grows inward rather than outward.⁶ The prognosis is excellent. When diagnosed using strict pathological criteria, inverted urothelial papilloma has about a 1% recurrence rate and is not considered related to urothelial carcinoma.⁷ A related growth, conventional urothelial papilloma, also follows a benign clinical course.⁸ If your pathology report comes back showing one of these, your doctor will likely recommend a simple follow-up schedule rather than aggressive treatment.

When a Lesion Is Precancerous

Flat lesions of the urothelium deserve more attention. Urothelial dysplasia and carcinoma in situ (CIS) are both flat (not raised or tumor-like) changes in the bladder lining that are considered precursors to invasive cancer.⁹ Dysplasia sits in a grey zone: the cells look abnormal but not abnormal enough to be classified as CIS. Older studies found that roughly 14–19% of dysplasia cases progressed to biopsy-proven carcinoma, with one study of de novo dysplasia (cases without any prior or coexisting tumor) showing a 19% progression rate to CIS or invasive cancer over an average of about two and a half years.¹⁰

CIS is more serious. Although it has not invaded deeper layers of the bladder wall, it is considered a high-grade lesion and carries a genuine risk of progressing to muscle-invasive disease if untreated. The tricky part is that CIS is flat, meaning it does not form an obvious mass. It can be invisible during a standard cystoscopy, which is one reason newer imaging methods have been developed to catch it.

Non-Muscle-Invasive Bladder Cancer

When a urothelial lesion is cancerous but has not grown into the bladder’s muscle layer, it falls under the umbrella of non-muscle-invasive bladder cancer (NMIBC). This is the category where most bladder cancers are caught. The WHO grading system divides these tumors into three main groups, each with a meaningfully different outlook: papillary urothelial neoplasm of low malignant potential (PUNLMP), low-grade papillary urothelial carcinoma, and high-grade papillary urothelial carcinoma. A large study of over 1,500 patients confirmed that PUNLMP had the lowest recurrence rate, while high-grade tumors that had begun invading the submucosal layer had the highest rates of progression and cancer-specific death.¹¹

If your pathology report says PUNLMP or low-grade cancer confined to the inner lining, the prognosis is generally favorable, though recurrences are common and require ongoing surveillance. High-grade non-muscle-invasive cancer is a different story: it demands more aggressive treatment and closer monitoring because of its potential to invade deeper.

How Urothelial Lesions Are Found

The most common reason a urothelial lesion gets discovered is blood in the urine. Painless visible blood in the urine is a warning sign that warrants a thorough workup, typically involving a physical exam, cystoscopy (a camera exam of the bladder), and imaging of the urinary tract.¹² Cystoscopy remains the gold standard for detecting bladder tumors, but it has limitations. Standard white-light cystoscopy can miss flat lesions like CIS.

Fluorescence-guided cystoscopy, which uses a light-sensitive agent (hexaminolevulinate) to make abnormal tissue glow under blue light, significantly improves detection. In one prospective study, blue-light cystoscopy flagged abnormalities in 8% of cases where white-light cystoscopy found nothing, and cancer was confirmed in 87% of those flagged cases.¹³ Another study found that fluorescence cystoscopy identified additional tumor lesions in about 27% of patients that white light alone had missed, including CIS lesions.¹⁴ The tradeoff is a higher false-positive rate, meaning some tissue that glows turns out to be benign on biopsy.

Urine cytology, where a pathologist examines shed cells from your urine, is often used alongside cystoscopy. It is excellent at detecting high-grade cancers and CIS, but it performs poorly for low-grade tumors.¹⁵ Newer urine-based tests that analyze DNA methylation and gene mutations have shown much higher sensitivity, reaching about 86% in one study of upper tract urothelial carcinoma compared to 29% for traditional cytology.¹⁶ These molecular tests are not yet routine everywhere but are increasingly being incorporated into clinical practice.

Risk Factors for Urothelial Lesions

The single biggest risk factor for developing a cancerous urothelial lesion is smoking. Cigarette smoke exposes the bladder lining to carcinogens that are filtered from the blood by the kidneys and concentrated in urine.¹⁷ Occupational exposure to aromatic amines, chemicals found in dye, rubber, paint, and chemical manufacturing, is the other major known driver. Arsenic in drinking water at high concentrations is also strongly associated with bladder cancer risk.¹⁸

Heavy metals play a role too. Elevated urinary levels of cadmium, chromium, nickel, and lead have been linked to an increased risk of urothelial carcinoma, with smokers showing particularly high urinary cadmium levels.¹⁹ For benign lesions like cystitis glandularis, the usual culprits are chronic urinary tract infections, bladder stones, prolonged catheter use, and other sources of ongoing bladder irritation rather than these environmental carcinogens.

How Treatment Differs Across the Spectrum

Benign lesions and benign tumors like inverted papilloma often require nothing beyond removal during cystoscopy and periodic follow-up. No chemotherapy, no radiation. Precancerous flat lesions and non-muscle-invasive cancers, on the other hand, are typically treated with transurethral resection (shaving away the abnormal tissue through a scope) followed by treatment delivered directly into the bladder.

The most established bladder-instilled therapy is BCG (bacillus Calmette-Guérin), a tuberculosis vaccine repurposed as an immunotherapy. It remains one of the success stories of cancer immunotherapy, with clinical effectiveness in over half of patients treated for superficial urothelial carcinoma.²⁰ BCG does cause local side effects in many patients, including bladder irritation and flu-like symptoms, and some patients do not respond to it at all. Global shortages of BCG in recent years have pushed clinicians toward alternatives like intravesical gemcitabine, a chemotherapy drug instilled into the bladder. Studies show gemcitabine has fewer side effects but higher recurrence rates: in one comparison, about 35% of patients receiving gemcitabine had their cancer recur versus about 16% with BCG.²¹ Progression rates were similar between the two, which offers some reassurance during periods when BCG is unavailable.

For tumors that have invaded the muscle wall or beyond, treatment escalates to major surgery (bladder removal), systemic chemotherapy, immunotherapy, or radiation. Upper tract urothelial cancers, which arise in the kidneys or ureters, are rarer and harder to evaluate. MRI is being studied as a tool for determining whether upper tract tumors have invaded the muscle layer, with promising early results showing high sensitivity in experienced hands.²²

The Surveillance Burden

One aspect of urothelial lesions that catches many patients off guard is how long follow-up lasts. Even after successful treatment of a low-grade, non-muscle-invasive tumor, you will likely need repeated cystoscopies for years, sometimes indefinitely. Bladder cancer has one of the highest recurrence rates of any cancer, which is why surveillance is so intensive. Risk stratification systems used by urologists sort patients into low, intermediate, and high-risk categories based on tumor characteristics, and the follow-up schedule adjusts accordingly.²³

This surveillance is not trivial for patients. Many people with non-muscle-invasive bladder cancer report significant discomfort and anxiety related to ongoing cystoscopies and the persistent worry about disease progression.²⁴ A study of over 200 bladder cancer patients in Indonesia found that close to half experienced some level of anxiety, and about 13% reported depression.²⁵ This psychological toll extends to caregivers as well. If you are in a surveillance program and finding it stressful, that reaction is common, not a sign of weakness.

Efforts to reduce the burden are underway. For patients with low-grade tumors, urine-based biomarkers may allow some cystoscopies to be safely skipped. One biomarker test showed a 99% negative predictive value for ruling out high-grade recurrence in low-grade patients, meaning a negative test result makes it very unlikely that a dangerous recurrence is being missed.²⁶ As these tools mature, they may spare low-risk patients from some of the most anxiety-provoking parts of the surveillance cycle.

Variant Histologies and Why Pathology Matters

About a quarter of urothelial carcinomas develop features that diverge from the “classic” appearance under the microscope. These variant histologies include subtypes like squamous differentiation, sarcomatoid features, micropapillary patterns, and others. Each variant behaves differently: some spread more aggressively, some respond better or worse to chemotherapy, and some express different targets for immunotherapy.²⁷ Because any single variant is uncommon, there is a real risk of missed diagnosis, which can lead to less-than-ideal treatment. Emerging genomic research is identifying distinct patterns of genetic alterations in these variant tumors, opening the door to more personalized, biomarker-driven therapy.²⁸

This is why getting a thorough pathology review matters, especially if you have been diagnosed with an unusual-looking tumor. If there is any ambiguity in the pathology report, seeking a second opinion from a specialized genitourinary pathologist is reasonable and something many urologists will encourage.

Diet, Fluids, and What You Can Actually Control

People newly diagnosed with a urothelial lesion often ask whether drinking more water or changing their diet could have prevented it or might slow a recurrence. The evidence here is thinner than many popular health sites suggest. A large European study found no association between total fluid intake and urothelial cancer risk, and no link was found for specific beverages like water, coffee, tea, or milk.²⁹ So the intuitive idea that “flushing out” the bladder with lots of water would protect against cancer does not hold up in the data.

What has shown a signal is the type of protein in your diet. The same European cohort found that a modest increase in energy from animal protein was associated with about a 15% higher risk of urothelial cancer, while a small increase in plant protein was associated with roughly a 23% lower risk.³⁰ These findings are from a single large observational study and need replication, but they align with broader patterns seen in cancer research linking high animal protein diets with increased risk of several cancer types. The most impactful lifestyle change, by a wide margin, remains quitting smoking if you currently smoke. No dietary adjustment comes close to the risk reduction that tobacco cessation offers for urothelial cancer.